197 related articles for article (PubMed ID: 28983968)
1. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K
Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
[TBL] [Abstract][Full Text] [Related]
3.
Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
[TBL] [Abstract][Full Text] [Related]
4. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
5. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
9. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W
JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553
[TBL] [Abstract][Full Text] [Related]
10. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
[TBL] [Abstract][Full Text] [Related]
11. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
Tolar J; Bostrom BC; La MK; Sather HN
Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
[TBL] [Abstract][Full Text] [Related]
12. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
13. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
14. 6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute lymphoblastic leukemia. Association with low (thio)purine enzyme activity.
De Abreu RA; Lambooy LH; Ahment K; Brouwer C; Keizer-Garritsen JJ; Bokkerink JP; Trijbels FJ
Adv Exp Med Biol; 2000; 486():271-5. PubMed ID: 11783498
[No Abstract] [Full Text] [Related]
15. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
17. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
18. 'Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia.
Mulla H; Buck H; Price L; Parry A; Bell G; Skinner R
J Oncol Pharm Pract; 2016 Jun; 22(3):387-95. PubMed ID: 25837624
[TBL] [Abstract][Full Text] [Related]
19. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
20. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K
Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
